All In Biotech

Drugs by condition

Drugs approved for parkinson's disease

Brand-name prescription drugs and biologics whose FDA label lists parkinson's disease as an approved use. Matched on the label phrases: "Parkinson".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

1

Still marketed, NDA or BLA

Drug classes

1

Novel drugs

0

New molecular entities and new biologics

In development

40+

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for parkinson's disease.

All approved drugs for parkinson's disease, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 25 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Class not listed in FDA's data (1)

Drugs in development for parkinson's disease

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • IRP101meta-fluorobenzylguanidine, 18F-MFBGPhase 34 trials

    Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · Cardiovascular Diseases, Heart Failure, Ischemic Cardiomyopathy

  • buntanetapposiphenPhase 33 trials

    Annovis Bio Inc. · Early Alzheimers Disease, Alzheimer's Dementia (AD), Parkinson's Disease (PD)

  • PrasinezumabRO7046015, PRX002Phase 33 trials

    Roche (Genentech) · Parkinson's Disease, Parkinsons Disease

  • RadotinibSupect, IY5511Phase 33 trials

    Il-Yang Pharm. Co., Ltd. · Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory

  • TJ0113Phase 33 trials

    Hangzhou PhecdaMed Co., Ltd. · Sarcopenia, Parkinson's Disease (PD), Parkinson Disease 6, Early-Onset

  • AMX0035Phase 32 trials

    Amylyx Pharmaceuticals Inc. · Wolfram Syndrome, Progressive Supranuclear Palsy, PSP

  • CVN424Phase 32 trials

    Cerevance · Parkinson Disease, Parkinson's Disease

  • GM1Phase 32 trials

    Qilu Pharmaceutical Co., Ltd. · Chemotherapy-induced Peripheral Neuropathy (CIPN), Parkinson's Disease

  • ONO-2808Phase 32 trials

    Ono Pharmaceutical Co., Ltd. · Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy (MSA)

  • bemdaneprocelMSK-DA01, BRT-DA01Phase 31 trial

    BlueRock Therapeutics · Parkinsons Disease (PD)

  • BHV-8000Phase 31 trial

    Biohaven Therapeutics Ltd. · Parkinson Disease

  • VG081821ACVG081821Phase 31 trial

    Zhejiang Vimgreen Pharmaceuticals, Ltd. · Parkinson Disease (PD)

  • Human Dopaminergic Progenitor CellsNouvNeu001Phase 23 trials

    iRegene Therapeutics Co., Ltd. · Parkinson Disease, Parkinson Disease (PD)

  • iPSChuman allogeneic induced pluripotent stem cell -derived dopaminergic neural progenitor cell, Allogeneic Human Induced Pluripotent Stem Cell -Derived Motor Neuron Progenitor CellsPhase 23 trials

    XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. · Spinal Cord Injury, Safety, Efficacy

  • AB-1005Phase 22 trials

    AskBio Inc · PARKINSON DISEASE (Disorder), Parkinson Disease

  • DNL151BIIB122Phase 22 trials

    Denali Therapeutics Inc. · Parkinson Disease

  • HBI-002Phase 22 trials

    Hillhurst Biopharmaceuticals, Inc. · Parkinson Disease, Anemia, Sickle Cell

  • NE3107bezisterimPhase 22 trials

    BioVie Inc. · Long COVID, Parkinsons Disease (PD)

  • RO7568282Phase 22 trials

    Roche (Genentech) · Parkinson's Disease, Alzheimer's Disease

  • VIM0423Phase 22 trials

    Vima Therapeutics · PARKINSON DISEASE (Disorder), Dystonia

More on parkinson's disease: recruiting trials · published research

Related in neurology: Alzheimer's disease · Multiple sclerosis · Epilepsy and seizures · Migraine · ALS (amyotrophic lateral sclerosis) · Myasthenia gravis · Spinal muscular atrophy · Duchenne muscular dystrophy · Huntington's disease chorea · Tardive dyskinesia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.